2018 Pancreatitis Drug Development- Pipeline Analysis Report
With an estimated prevalence of around 20 million pancreatitis cases worldwide, it is one of the most devastative gastrointestinal diseases. On the basis of duration of the disease existence, it is typically classified as acute pancreatitis and chronic pancreatitis. Of this, acute pancreatitis lasts from few days to months and can occur suddenly. On the other hand, the chronic pancreatitis develops over years and can last for few years.
Around 25 companies and universities are focusing on developing treatment options for Pancreatitis.
To assist investigators and funding and regulatory organizations, VPA Research has come up with a comprehensive report on Pancreatitis pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.
Current status, developmental phase, participating companies and entities, recent developments, orphan drug/fast track/other designations, drug class are provided for each Pancreatitis pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.
In addition to complete details of each product, the report provides key trends in Pancreatitis pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.
Around 25 companies and universities are focusing on developing treatment options for Pancreatitis.
To assist investigators and funding and regulatory organizations, VPA Research has come up with a comprehensive report on Pancreatitis pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.
Current status, developmental phase, participating companies and entities, recent developments, orphan drug/fast track/other designations, drug class are provided for each Pancreatitis pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.
In addition to complete details of each product, the report provides key trends in Pancreatitis pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.
1 TABLE OF CONTENTS
1.1 List of Figures
1.2 List of Tables
2 PANCREATITIS PIPELINE ANALYSIS
2.1 Disease and Pipeline Overview
2.2 Pancreatitis Pipeline Snapshot
2.3 Pancreatitis Pipeline by Phase
2.4 Pancreatitis Pipeline by Company
2.5 Pancreatitis Pipeline by Mechanism of Action
3 PANCREATITIS- COMPANY WISE PIPELINE ANALYSIS
AzurRx BioPharma
Bessor Pharma LLC
Bharat Serums And Vaccines Ltd
CalciMedica
Centeer BioTherapeutics
Centeer BioTherapeutics
Cypralis
DiaMedica Therapeutics
Generon (Shanghai) Corp
GlaxoSmithKline
GNT Pharma
Immungenetics
LipimetiX Development
MallInckrodt
Pharming Group
Stason Pharmaceuticals
Sun BioPharma
Takeda Pharmaceutical
4 PANCREATITIS R&D PIPELINE SNAPSHOTS
Drug wise Pipeline Details
Therapeutic Candidate Name
Originator
Co-Developer/License Partner
Orphan Drug Designation
Development Phase
Mechanism of Action
Current Status
Ongoing Clinical Trial Details
5 RECENT DEVELOPMENTS IN PANCREATITIS PIPELINE
6 APPENDIX
6.1 About VPA Research
6.2 Sources and Research Methodology
1.1 List of Figures
1.2 List of Tables
2 PANCREATITIS PIPELINE ANALYSIS
2.1 Disease and Pipeline Overview
2.2 Pancreatitis Pipeline Snapshot
2.3 Pancreatitis Pipeline by Phase
2.4 Pancreatitis Pipeline by Company
2.5 Pancreatitis Pipeline by Mechanism of Action
3 PANCREATITIS- COMPANY WISE PIPELINE ANALYSIS
AzurRx BioPharma
Bessor Pharma LLC
Bharat Serums And Vaccines Ltd
CalciMedica
Centeer BioTherapeutics
Centeer BioTherapeutics
Cypralis
DiaMedica Therapeutics
Generon (Shanghai) Corp
GlaxoSmithKline
GNT Pharma
Immungenetics
LipimetiX Development
MallInckrodt
Pharming Group
Stason Pharmaceuticals
Sun BioPharma
Takeda Pharmaceutical
4 PANCREATITIS R&D PIPELINE SNAPSHOTS
Drug wise Pipeline Details
Therapeutic Candidate Name
Originator
Co-Developer/License Partner
Orphan Drug Designation
Development Phase
Mechanism of Action
Current Status
Ongoing Clinical Trial Details
5 RECENT DEVELOPMENTS IN PANCREATITIS PIPELINE
6 APPENDIX
6.1 About VPA Research
6.2 Sources and Research Methodology
LIST OF FIGURES
Figure 1: Pancreatitis Pipeline by Phase, H1- 2018
Figure 2: Pancreatitis Pipeline by Companies, H1- 2018
Figure 3: Company Wise Pipeline Drug Phases, H1- 2018
Figure 4: Pancreatitis Pipeline by Mechanism of Action, H1- 2018
Figure 5: Mechanism Wise Pipeline Drug Phases, H1- 2018
Figure 1: Pancreatitis Pipeline by Phase, H1- 2018
Figure 2: Pancreatitis Pipeline by Companies, H1- 2018
Figure 3: Company Wise Pipeline Drug Phases, H1- 2018
Figure 4: Pancreatitis Pipeline by Mechanism of Action, H1- 2018
Figure 5: Mechanism Wise Pipeline Drug Phases, H1- 2018
LIST OF TABLES
Table 1: Pancreatitis Pipeline by Phase, H1- 2018
Table 2: Pancreatitis Pipeline by Companies, H1- 2018
Table 3: Pancreatitis Pipeline by Mechanism of Action, H1- 2018
Table 4: AzurRx BioPharma Pancreatitis Pipeline, May 2018
Table 5: Bessor Pharma LLC Pancreatitis Pipeline, May 2018
Table 6: Bharat Serums And Vaccines Ltd Pancreatitis Pipeline, May 2018
Table 7: CalciMedica Pancreatitis Pipeline, May 2018
Table 8: Centeer BioTherapeutics Pancreatitis Pipeline, May 2018
Table 9: Centeer BioTherapeutics Pancreatitis Pipeline, May 2018
Table 10: Cypralis Pancreatitis Pipeline, May 2018
Table 11: Cypralis Pancreatitis Pipeline, May 2018
Table 12: DiaMedica Therapeutics Pancreatitis Pipeline, May 2018
Table 13: Generon (Shanghai) Corp Pancreatitis Pipeline, May 2018
Table 14: GlaxoSmithKline Pancreatitis Pipeline, May 2018
Table 15: GNT Pharma Pancreatitis Pipeline, May 2018
Table 16: Immungenetics Pancreatitis Pipeline, May 2018
Table 17: LipimetiX Development Pancreatitis Pipeline, May 2018
Table 18: MallInckrodt Pancreatitis Pipeline, May 2018
Table 19: Pharming Group Pancreatitis Pipeline, May 2018
Table 20: Stason Pharmaceuticals Pancreatitis Pipeline, May 2018
Table 21: Sun BioPharma Pancreatitis Pipeline, May 2018
Table 1: Pancreatitis Pipeline by Phase, H1- 2018
Table 2: Pancreatitis Pipeline by Companies, H1- 2018
Table 3: Pancreatitis Pipeline by Mechanism of Action, H1- 2018
Table 4: AzurRx BioPharma Pancreatitis Pipeline, May 2018
Table 5: Bessor Pharma LLC Pancreatitis Pipeline, May 2018
Table 6: Bharat Serums And Vaccines Ltd Pancreatitis Pipeline, May 2018
Table 7: CalciMedica Pancreatitis Pipeline, May 2018
Table 8: Centeer BioTherapeutics Pancreatitis Pipeline, May 2018
Table 9: Centeer BioTherapeutics Pancreatitis Pipeline, May 2018
Table 10: Cypralis Pancreatitis Pipeline, May 2018
Table 11: Cypralis Pancreatitis Pipeline, May 2018
Table 12: DiaMedica Therapeutics Pancreatitis Pipeline, May 2018
Table 13: Generon (Shanghai) Corp Pancreatitis Pipeline, May 2018
Table 14: GlaxoSmithKline Pancreatitis Pipeline, May 2018
Table 15: GNT Pharma Pancreatitis Pipeline, May 2018
Table 16: Immungenetics Pancreatitis Pipeline, May 2018
Table 17: LipimetiX Development Pancreatitis Pipeline, May 2018
Table 18: MallInckrodt Pancreatitis Pipeline, May 2018
Table 19: Pharming Group Pancreatitis Pipeline, May 2018
Table 20: Stason Pharmaceuticals Pancreatitis Pipeline, May 2018
Table 21: Sun BioPharma Pancreatitis Pipeline, May 2018
